Company intelligence / Profile preview

OCON Therapeutics

Ownership: Private
Development stage: Phase 2

Overview

OCON Therapeutics has developed a proprietary intrauterine ball (IUB) drug-delivery platform with over 150,000 women treated using its lead product, the hormone-free contraceptive IUB Ballerine®. The company’s pipeline includes innovative devices targeting abnormal uterine bleeding and endometriosis. Clinical data support safety and usability of the platform. The company recently secured $10M funding to advance its next-generation products through late-stage trials and regulatory approvals.

Therapeutic areas: Women's Health
Modalities: DeviceDrug delivery system (intrauterine)Hormone-free contraceptive device (IUB Ballerine®)Local hormone delivery (IUB PRIMA®)
Industry: Implantable Medical Devices

Drug pipeline

5 assets

IUB Ballerine

Commercial

Indications: Contraception

4 more assets in the full pipeline.

Request access →

Partnerships

Distribution agreements worth $45 million including Canada and Mexico for IUB Ballerine®. No major pharma partnerships disclosed yet.

Beyond the preview

Go deeper on OCON Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OCON Therapeutics.

Explore the full profile